Replies to post #80194 on Biotech Values

[ghmm]

MNTA:

I was curious about the same. I think the partner likely picks up most of the development costs which probably limits the up-front amount and back-ends quite a bit.

[DewDiligence]

MNTA: …any guesstimates on how much money MNTA may be able to garner in an up-front milestone payment from a partner given these trial results? $10 million? $30 million? Higher?

I’m not going to try to handicap this until MNTA reports the full data set at a medical conference. However, I think we can infer that the M118 partnership prospects (combined with the easing of the credit markets since early 2009) give MNTA the confidence to not rush into a financing deal on less than excellent terms. This may be the consequential effect of the M118 data on the share price in the short run.